SCY-078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species. This was a sequential, single-center, openlabel phase 1 study to assess the drug-drug interaction potential between SCY-078 and tacrolimus during concomitant administration in healthy subjects. In cohort 1, period 1, subjects received a single oral dose of tacrolimus 2 mg in the fasted state. In period 2 after a ࣙ15 day washout, subjects received a single loading dose of SCY-078 1250 mg on day 1 followed by maintenance doses of SCY-780 750 mg on days 2 through 8. On day 3 of period 2, subjects also received a single dose of tacrolimus 2 mg concurrent with SCY-078. In cohort 2, subjects received a loading dose of SCY-078 1250 mg on day 1 followed by maintenance doses of SCY-780 750 mg on days 2 and 3. Pharmacokinetic (PK) parameters were compared to assess both the impact of steady-state SCY-078 on tacrolimus and the impact of tacrolimus on the PK of steady-state SCY-078. The concurrent coadministration of tacrolimus and SCY-078 had no effect on the maximum blood levels of tacrolimus, as evidenced by no change in maximum concentration of drug in blood plasma and a 1.4-fold increase in total area under the plasma drug concentration-time curve. The concurrent coadministration of tacrolimus and SCY-078 resulted in a weaker interaction than typically observed with the azole class of antifungals. The current data indicate that an initial dose adjustment for tacrolimus may not be warranted when combined with SCY-078, as the modest increase in exposure is less than the therapeutic window, although tacrolimus monitoring, as with addition of any new medication, is recommended. These results support the coadministration of SCY-078 and tacrolimus.
SCY-078 is an orally bioavailable triterpenoid glucan synthase inhibitor in clinical development as an intravenous and oral treatment of fungal infections caused by Candida and Aspergillus species. The chemical structure of SCY-078 and the nonclinical pharmacokinetic characterization has been reported by Wring et al. 1 SCY-078 has demonstrated antifungal activity across murine models of disseminated candidiasis 1, 2 or aspergillosis 3 and in vitro against wild-type and azole-resistant isolates of Aspergillus and Candida species, and in clinically relevant Candida isolates with multidrug-resistant phenotypes, including Candida auris. [4] [5] [6] [7] [8] Invasive fungal infections caused by these organisms represent a serious problem in critically ill patients, particularly those with compromised immune responses, including patients receiving solid-organ or stem cell transplants, causing considerable morbidity and mortality. 9 SCY-078 is fungicidal against Candida species, in contrast to the fungistatic behavior of the azole class of antifungals. 10 Recently, SCY-078 has achieved clinical proof-of-concept end points in oral phase 2 clinical studies for invasive candidiasis and vulvovaginal candidiasis. [11] [12] [13] Thus far, oral SCY-078 has been administered to more than 400 healthy human subjects or patients during the clinical development program. After oral single-dose administration peak, plasma SCY-078 concentrations occur within ß4 to 6 hours postdose. Plasma concentrations decline from maximum concentration of drug in blood plasma (C max ) in an approximately monophasic decline with a mean terminal half-life of ß20 to 30 hours. Values for C max and total area under the plasma drug concentration-time curve (AUC) appeared, in general, to increase proportionally with dose over the range 10 mg to 1600 mg. The regimen used for completed phase 2 studies comprised a single 1250-mg loading dose on day 1 of treatment followed by daily maintenance doses of 750 mg, consistent with the regimen employed for the current study. This strategy rapidly achieved the exposure target for antifungal activity (AUC 0-24 , ࣙ15.4 μM · h, ࣙ11.24 μg · h/mL). 1 Patients who have undergone transplants are at high risk of opportunistic fungal infections, primarily due to Candida and Aspergillus species. [14] [15] [16] Many transplant recipients receive either cyclosporine A or, more frequently, tacrolimus as immunosuppressants to prevent or treat allograft rejection. Given the potential for dose-related adverse experiences and loss of efficacy, therapeutic drug monitoring of tacrolimus is recommended for all patients. Most patients are stable when trough whole blood concentrations (which are highly correlated with AUC) are maintained between 5 and 20 ng/mL. Antifungal agents are commonly administered in these patients either as prophylaxis or as treatment of fungal infections and, considering the long duration of these regimens, orally administered antifungal agents are desirable. There is a significant limitation in the antifungal armamentarium available to date in regards to safety and ease of concurrent use with tacrolimus, particularly considering that the azoles (the only orally available class of antifungals) are moderate to strong inhibitors of cytochrome P450 3A (CYP3A), the key CYP isoform responsible for metabolism of tacrolimus, 17, 18 and may cause a marked (2-to 5-fold) increase in tacrolimus blood levels resulting in the need for dose adjustments and increased clinical management to reduce the risk of drug-related toxicities. 19, 20 Indeed, Groll et al 21 recently summarized the magnitude of potential drug-drug interactions between azoles and tacrolimus in which they state that isavuconazole, itraconazole, posaconazole, and voriconazole may increase exposure (as either AUC or C trough ) by approximately 2.3, 5.6, 3.6, and 3-fold, respectively. These data led to a recommendation for a 50% to 75% dose reduction and frequent monitoring of tacrolimus blood levels when coadministered with azoles. 21 In contrast, in vitro data support that at clinically relevant exposures SCY-078 will have no or weak effects on sensitive CYP3A4 substrates such as midazolam or tacrolimus (<2-fold increase in substrate exposure). 22 The primary objective of this study is to assess the effect of SCY-078 on tacrolimus.
As a further challenge to patient management, tacrolimus is an inhibitor of CYP3A and may thus impact the exposure of concomitantly administered drugs should they be metabolized by this isoform. Consequently, in assessing the safety of administering drugs with tacrolimus, it is important to consider the potential for tacrolimus to be either a victim or a perpetrator of an interaction. An oral antifungal agent with low risk for interaction with tacrolimus would provide a safer alternative compared with the azoles for the treatment and prevention of invasive fungal infections in the transplant population. Moreover, an oral agent that is active against azole-resistant isolates would provide a new treatment option in transplant patients with difficult-to-treat fungal infections.
In vitro studies have shown that SCY-078 is a substrate of CYP3A and P-glycoprotein that neither induces CYP3A activity or messenger RNA nor acts as a time-dependent inhibitor of CYP3A. Nonetheless, as a CYP3A4 substrate, it has the potential for interactions with tacrolimus. Thus, the current study was designed to evaluate the potential for SCY-078 to be either a perpetrator or a victim of drug-drug interactions when coadministered with tacrolimus.
We present results from a sequential, single-center, open-label phase 1 drug-drug interaction study to assess the potential for SCY-078 dosed to steady state at therapeutically relevant levels, to either increase exposure to tacrolimus or for tacrolimus to increase exposure to SCY-078 during concomitant administration.
Methods
The clinical study was conducted at Worldwide Clinical Trials (Austin, Texas) in full compliance with the principles of the Declaration of Helsinki, International Conference on Harmonization guidelines, and all of the applicable regulations of the US Code of Federal Regulations. The study protocol and informed consent were reviewed and approved by an institutional review board (IntegReview IRB, Austin, Texas). All subjects provided written informed consent prior to performance of any study procedures. 
Study Objectives
The objectives of this study were to (1) compare the exposure (AUC 0-Ý and C max ) of tacrolimus 2 mg alone and when coadministered with SCY-078; (2) determine the exposure for SCY-078 after a single oral 1250-mg dose, after multiple doses of 750-mg SCY-078, and after coadministration with tacrolimus 2 mg; and (3) assess the safety and tolerability of tacrolimus 2 mg, multiple doses of SCY-078, and the coadministration of tacrolimus 2 mg after multiple doses of SCY-078.
Study Design
This was a phase 1, single-center, open-label, sequential study conducted in 2 cohorts of healthy male subjects. Subjects in cohort 1 were studied in 2 periods, period 1 (single-dose tacrolimus) and period 2 (single-dose tacrolimus with steady-state SCY-078), separated by a washout of ࣙ15 days. Subjects in cohort 2 (SCY-078 alone) were studied in parallel with cohort 1, period 2 ( Figure 1) . A sequential design was used in cohort 1 due to the long half-life of SCY-078. Cohort 2 was added to assess and compare SCY-078 exposures in the absence of tacrolimus administration with SCY-078 exposure with tacrolimus dosing in cohort 1 in a descriptive manner.
Cohort 1. In Period 1, subjects received a single oral dose of 2 mg tacrolimus (Astellas Pharma Inc., Tokyo, Japan; 4 × 0.5-mg capsules) in the fasted state. Blood samples were collected predose (time 0), and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 , and 144 hours postdose for analysis of tacrolimus concentrations. In period 2 (after a washout period of ࣙ15 days), subjects received a single loading dose of 1250-mg SCY-078 as a citrate salt (SCYNEXIS, Inc., Jersey City, New Jersey; 5 × 250-mg tablets) on day 1 followed by daily maintenance doses of 750-mg SCY-780 (3 × 250-mg tablets) on days 2 through 8. On day 3 of period 2, subjects also received a single dose of 2-mg tacrolimus concurrent with SCY-078. Blood samples for analysis of SCY-078 concentrations were collected at predose on day 1 of period 2 (time 0), and at 0. 
Study Population
Healthy male volunteers aged 18 to 50 years (inclusive) with a body mass index of ࣘ32 kg/m 2 were eligible. Subjects were nonsmokers who had not used nicotine or nicotine-containing products for at least 3 months. Subjects with impaired renal function (estimated creatinine clearance ࣘ80 mL/min) or a history of liver disease (including chronic hepatitis or clinically significant elevated liver enzymes) and those at risk for QT prolongation or torsade de pointes were excluded from the study. Also excluded were subjects with a history of clinically significant endocrine, respiratory, gastrointestinal, cardiovascular, hematological, immunological, metabolic, or major neurological disorders or renal, dermatologic, or genitourinary abnormalities or diseases. All medications (including prescription and over-the-counter medications, supplements, and herbal products) taken within 28 days of randomization and until 14 days after the last dose of study medication were recorded.
Subjects had to refrain from participating in strenuous exercise throughout the study and wear protective clothing and use sunscreen with a high protection factor during exposure to sunlight and ultraviolet light.
Study Procedures. Subjects in both cohorts were admitted to the clinical research facility on day -1 of each period and were required to remain at the facility for 72 hours postdose of tacrolimus or until discharged (cohort 1, period 1 was discharged 72 hours post tacrolimus on day 1; and cohort 1, period 2 was discharged 72 hours post tacrolimus on day 3). Subjects returned to the research facility for subsequent blood samples to be collected. These outpatient samples were collected as close to the exact sampling time point as possible, but a window of ±15 minutes was permitted; the exact sampling time was recorded.
On all dosing days, study medications (SCY-078 and tacrolimus) were administered to subjects in both cohorts in the fasted state. Subjects refrained from consuming food and drink (except water) for at least 10 hours before dosing. Water was restricted for 1 hour before and until 1 hour after drug administration. While subjects were resident in the research facility, meals were provided at 4 and 10 hours postdose, with a snack offered at 7 and 13 hours postdose. Care was taken to ensure that meals had equivalent caloric content and composition in each treatment period. Once the 24-hour postdose procedures were completed, subsequent meals and snacks were unrestricted in caloric content, composition, and timing. Subjects were required to refrain from consuming alcohol within 1 week prior to study start and caffeinated beverages for 48 hours before clinical admission; both substances were prohibited throughout the study (including the 15-day washout between treatment periods). A follow-up visit occurred approximately 14 days after the last dose of SCY-078.
Pharmacokinetic Evaluations
All blood samples were collected into tubes containing K2-ethylenediaminetetraacetic acid anticoagulant. Tacrolimus concentrations were measured in whole blood due to extensive distribution into erythrocytes, 23 and SCY-078 concentrations were measured in plasma. Samples were stored at approximately -70°C until analyzed. SCY-078 and tacrolimus concentrations were determined by Agilux Laboratories (Worcester, Massachusetts) using validated liquid chromatography with tandem mass spectrometry methods with appropriate calibration standards and quality controls. All reported data met acceptance criteria comprising accuracy within ±15% for calibration standards and quality control samples, with the exception of ±20% accuracy at the lower limit of quantitation. Incurred sample reanalyses for SCY-078 and tacrolimus met acceptance criteria.
Methods of Bioanalysis for SCY-078 and Tacrolimus
SCY-078 and tacrolimus detection was achieved using electrospray ionization (positive ion mode) on an API5500 mass spectrometer system (Sciex, Concord, Ontario, Canada).
SCY-078 was quantified in 20-μL aliquots of plasma following treatment by protein precipitation covering an assay range of 5 to 5000 ng/mL with d9-SCY-078 as the internal standard. Chromatography was performed by gradient elution from an Advanced Chromatography Technologies (Aberdeen, Scotland) ACE 3 C18 (50 × 2.1 mm) high-performance liquid chromatography column. A binary mobile phase system was employed comprising (1) 0.1% formic acid in purified water and (2) 0.1% formic acid in acetonitrile. The precursor/product ion transitions for tandem mass spectrometry were 730.4/584.4 and 739.5/593.6 m/z for SCY-078 and d9-SCY-078, respectively (dwell time, 100 milliseconds).
Tacrolimus was quantified in 100-μL aliquots of whole blood after protein precipitation followed by solid phase extraction on Waters (Milford, Massachusetts) Oasis HLB LP 60 μm (60 mg) 96-well plates, over an assay range of 0.1 to 100 μg/mL, with ascomycin as the internal standard.
Chromatography was performed by gradient elution from a Waters XBridge C18 (50 × 2.1 mm) highperformance liquid chromatography column. A binary mobile phase system was employed comprising (1) 5 mM ammonium acetate in purified water and (2) 100% methanol. The precursor/product ion transitions for tandem mass spectrometry were 821.5/768.5 and 809.5/756.4 m/z for tacrolimus and ascomycin, respectively (dwell time, 150 milliseconds and 50 milliseconds, respectively).
Pharmacokinetic Analyses and Statistical Methods
Statistical analysis was performed with SAS Version 9.3 (SAS Institute, Cary, North Carolina). Assuming an expected mean exposure ratio of 1 for Test (tacrolimus + SCY-078)/Reference (tacrolimus alone) and an intersubject percent coefficient of variation of 25%, a sample size of 24 subjects in cohort 1 was considered sufficient to achieve the 90% confidence intervals (CIs) within the no-effect limits of 0.8 to 1.25 on the geometric means ratio (GMR) for whole blood tacrolimus AUC 0-Ý and C max . 24 A sample size of 12 subjects for cohort 2 was considered sufficient to adequately assess exposure of SCY-078 following a loading dose of 1250 mg on day 1 of treatment and on day 3 after 2 daily maintenance doses of 750-mg SCY-078.
SCY-078 and tacrolimus PK parameters for C max and AUC were log transformed before analysis. 25 GMR and CIs of tacrolimus co-administered with SCY-078 compared to tacrolimus administered alone were calculated based on linear mixed-effects model: log PK result = treatment + subject. Safety was monitored throughout the study by medical review of adverse event (AE) reports, physical examinations, electrocardiograms, and clinical laboratory tests. Summary statistics were generated for safety parameters, but no statistical testing was performed.
Results
A total of 36 healthy male subjects, mean (standard deviation) age 37.6 years, were enrolled and randomized: 24 subjects were included in cohort 1, and 12 were included in cohort 2. Thirty-five subjects completed the study. One subject in cohort 1 was discontinued by the investigator after period 1 (ie, received only tacrolimus) due to mildly elevated liver enzymes. Data for this subject were excluded from the PK population analysis.
Pharmacokinetics of Tacrolimus (Cohort 1)
Mean (standard deviation) whole blood concentrationtime profiles following a single dose of tacrolimus 2 mg alone (period 1, day 1) and after coadministration 
Pharmacokinetics of SCY-078
For cohort 2, the concentration-time profiles of SCY-078 in plasma after a single loading dose of SCY-078 1250 mg on day 1 and after the second daily dose of SCY-078 750 mg on day 3 are shown in Figure 3 . SCY on day 1 and comparable exposure on day 1 and day 3 indicates the loading dose subjects achieved steadystate exposures consistent with repeated daily doses of 750 mg as measured on day 3. The therapeutic AUC 0-24 target of 11.24 ng · h/mL 1 was achieved on day 1 and maintained on day 3 of treatment. Plasma SCY-078 concentration-time profiles after a single loading dose of SCY-078 1250 mg on day 1 and SCY-078 750 mg on days 2 and 3 either with (cohort 1, period 2) or with- out tacrolimus (cohort 2) are shown in Figure 4 . Plasma SCY-078 PK parameters for Cohorts 1 and 2 are shown in Table 2 .
Administration of SCY-078 alone resulted in a C max of 0.83 ng/mL, AUC 0-24h of 13.4 ng · h/mL and t max of 5.0 hours (cohort 2, day 3). Coadministration of SCY-078 with tacrolimus (cohort 1, period 2, day 3) resulted in comparable SCY-078 PK parameters: C max 0.87 ng/mL, AUC 0.24h 14.0 ng · h/mL and t max 6.0 hours ( Table 2) , indicating no effect of tacrolimus coadministration on SCY-078 PK parameters.
Safety and Tolerability
Overall, 19 subjects (52.8%) reported at least 1 treatment-emergent AE. One subject discontinued the study due to elevated liver function tests (alanine aminotransferase and aspartate aminotransferase) after receiving a tacrolimus dose only in cohort 1, period 1; these laboratory abnormalities were not deemed clinically significant, but the subject was discontinued from dosing in the next study period because laboratory values were inconsistent with the study inclusion criteria.
The most common treatment-emergent AEs were gastrointestinal: diarrhea, abdominal pain, nausea, vomiting, and flatulence (Table 3 ). All treatment-emergent AEs were mild or moderate in intensity. No serious AEs were reported and no subjects discontinued the study due to an AE.
Discussion
Tacrolimus is an immunosuppressant drug often administered to solid-organ transplant patients to prevent and treat allograft rejection. As transplant patients are highly susceptible to invasive fungal infections, especially those caused by Candida and Aspergillus species, 14, 15 antifungal agents are often coadministered with tacrolimus either as prophylaxis or for the treatment of fungal infections. Tacrolimus is cleared almost exclusively by metabolism via the cytochrome P450 enzyme system with the CYP3A isoforms responsible for approximately 90% of metabolism. 26 It is estimated that a drug interaction is most likely to be clinically relevant when the metabolic fraction of a specific pathway being inhibited exceeds 50% of the total clearance. 27 Because CYP3A-mediated metabolism of tacrolimus is responsible for >90% of its phase 1 oxidative metabolic elimination, marked inhibition or induction of CYP3A isoforms may lead to a clinically significant PK drug interaction. Coadministering drugs with tacrolimus has the potential to affect systemic exposure of either drug; however, perhaps the most important are those that impact tacrolimus leading to alterations in the immunosuppressant concentration. Azoles, the only available oral class of antifungals, 28 as described above, may cause a marked increase in tacrolimus blood levels, necessitating dose adjustment of tacrolimus to avoid toxicities. Without tacrolimus dose adjustment and drug monitoring, 19, 20 this potentially puts the patient at high risk for either toxicity or transplant rejection. The echinocandin class of antifungals, 28 in contrast with the azoles, is associated with a much lower risk of drugdrug interactions; however, they are available only for intravenous administration. 28 In vitro studies (Wring SA, Park SM, Unpublished data on file, SCYNEXIS, Inc.) in human liver microsomes indicated SCY-078 was a reversible inhibitor of CYP2C8 (half maximal inhibitory concentration value of 1.5 μM, 1.09 μg/mL) and CYP3A4 (7.2 μM, 5.26 μg/mL). The half maximal inhibitory concentration values were >25 μM (18.25 μg/mL) for inhibition of CYP1A2, 2B6, 2C9, 2C19, and 2D6.
A clinical drug-drug interaction study to evaluate the potential for SCY-078 to impact exposure for the CYP2C8 substrate rosiglitazone coadministered with steady-state SCY-078 (Test) versus rosiglitazone alone (Reference) indicated least squares mean values based on Test/Reference GMR (90%CI) results of AUC0-Ý, C max , and AUC 0-24h were 0.99 (0.90, 1.10), 0.80 (0.70, 0.90) and 0.98 (0.89, 1.08), respectively. 29 In vitro SCY-078 was not a time-dependent inhibitor of CYP3A4, an activator of human PXR (half maximal response concentration >30 μM [21.9 μg/mL]; <10% activation relative to rifampicin at 10 μM), or an inducer of human CYP3A4 at concentrations ࣘ10 μM. SCY-078 metabolism was predominantly oxidative in nonrodent species and humans. An inhibitory anti-CYP3A antibody almost completely inhibited the metabolism of SCY-078 (10 μM) in human liver microsomes, suggesting that CYP3A is the primary enzyme involved in the oxidative metabolism of SCY-078. Incubation with other major anti-P450 antibodies had minimal or no effect on the metabolism of SCY-078.
In vitro studies in LLC-PK1 cells showed that SCY-078 was a P-glycoprotein substrate with BA/AB ratios of 3.2 and 4.4 in cells transfected with the human MDR1 and mouse Mdr1a, respectively. Overall, the in vitro characterization indicated SCY-078 is a substrate for CYP3A4 and P-glycoprotein.
The aim of this study was to characterize the propensity of SCY-078 to be either a perpetrator or victim of drug-drug interactions with tacrolimus. The tacrolimus dose selected for this study was based on regulatory guidance for potential substrates in drug-drug interaction studies when a large effect may impact subject safety. 30 The results of this study show that coadministration of a single-dose of tacrolimus with SCY-078 at steady state resulted in a modest 1.4-fold increase in systemic exposure to tacrolimus (AUC 0-Ý ) and 1.7-and 1.5-fold increases in trough concentrations (C 12 and C 24 ) compared with administration of tacrolimus alone, consistent with SCY-078 being a weak inhibitor of CYP3A4 (AUC increased by ࣙ1.25-fold but ࣘ2-fold).
21,22 C max and t max of tacrolimus were similar whether given alone or with SCY-078. These data indicate a lower risk for clinically meaningful effect of SCY-078 on tacrolimus exposure than seen with the azoles. Furthermore, these data are supportive that tacrolimus may be coadministered with SCY-078 with no tacrolimus dose adjustment in combination with monitoring of tacrolimus trough concentrations.
Given the potential for dose-related adverse experiences and loss of efficacy, therapeutic drug monitoring of tacrolimus is recommended for all patients. Most patients are stable when trough whole blood concentrations (which correlate with AUC) are maintained between 5 and 20 ng/mL. Long-term posttransplant patients often are maintained at the lower end of this target range.
An additional goal of this study was to preliminarily evaluate the effect of tacrolimus on SCY-078. Tacrolimus has a mild inhibitory effect on CYP3A4 17 in vitro and is unlikely to potentiate the effect of coadministered drugs through inhibition of their metabolism in the liver. Tacrolimus had no effect on SCY-078 concentrations in this study, although the interaction was studied after only 1 reduced dose of tacrolimus. Additional study would be needed to exclude an effect of tacrolimus on SCY-078 concentrations with the usual twice-daily tacrolimus administration, although given the mild inhibitory effect of tacrolimus, the risk of increased SCY-078 exposures is judged to be low.
Conclusions
The concurrent coadministration of tacrolimus and SCY-078 had no effect on the maximum blood levels of a single dose of tacrolimus, as evidenced by no change in C max and only a 1.4-fold increase in AUC for tacrolimus, reflecting a markedly weaker interaction than typically observed with the azole class of antifungals (2.3-to 5.6-fold increase in the AUC of tacrolimus). Tacrolimus had no measurable impact on the PK of SCY-078. These data are supportive for the coadministration of SCY-078 and tacrolimus. The current data indicate that an initial dose adjustment for tacrolimus may not be warranted when combined with SCY-078, although tacrolimus monitoring, as with addition of any new medication, is recommended.
